Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
136.38
-1.36 (-0.99%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 57.83M EUR in the quarter ending September 30, 2024, with 20.40% growth. This brings the company's revenue in the last twelve months to 327.43M, up 115.54% year-over-year. In the year 2023, Ascendis Pharma had annual revenue of 266.72M with 421.20% growth.
Revenue (ttm)
327.43M EUR
Revenue Growth
+115.54%
P/S Ratio
21.32
Revenue / Employee
372,499 EUR
Employees
879
Market Cap
8.15B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walgreens Boots Alliance | 147.66B |
The Ensign Group | 4.11B |
Jazz Pharmaceuticals | 3.99B |
Teleflex | 3.03B |
Chemed | 2.38B |
HealthEquity | 1.15B |
Repligen | 633.51M |
Glaukos | 360.35M |
ASND News
- 2 days ago - YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults - GlobeNewsWire
- 5 days ago - New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26 - GlobeNewsWire
- 9 days ago - FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 11 days ago - Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets - GlobeNewsWire
- 5 weeks ago - Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Ascendis Pharma Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 2 months ago - New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024 - GlobeNewsWire